Immunoregulatory role of CD8α in the veto effect: Transforming growth factor-b1 activation

Transplantation

Volumn 67, Issue 3, 1999, Pages 372-380

  Asiedu, Clement ^a   Meng, Yuru ^a   Wang, Weila ^a   Huang, Zhi ^a   Contreras, Juan L ^a   George, James F ^a   Thomas, Judith M ^a,b  

^a UAB Department of Surgery   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD3 ANTIGEN; CD8 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA1; CROSS LINKING REAGENT; DNA FRAGMENT; FC RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

ALLOGENEIC RESTRICTION; ANTIBODY COMBINING SITE; ARTICLE; BONE MARROW CELL; CROSS LINKING; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMATOPOIETIC CELL; HISTOCOMPATIBILITY; HYPOTHESIS; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; LYMPHOCYTOTOXICITY; MACACA; MIXED LYMPHOCYTE REACTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ALLOTRANSPLANTATION; ANIMAL; BIOSYNTHESIS; BONE MARROW TRANSPLANTATION; CD8+ T LYMPHOCYTE; CELL CULTURE; CYTOLOGY; GENETIC TRANSCRIPTION; GENETICS; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE DEPLETION; LYMPHOCYTE TRANSFUSION; MAJOR HISTOCOMPATIBILITY COMPLEX; METHODOLOGY; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIGENS, CD8; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CROSS-LINKING REAGENTS; DNA FRAGMENTATION; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; LYMPHOCYTE DEPLETION; LYMPHOCYTE TRANSFUSION; MACACA MULATTA; MAJOR HISTOCOMPATIBILITY COMPLEX; PROTEIN BIOSYNTHESIS; RECEPTORS, IGG; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA; TRANSPLANTATION, HOMOLOGOUS;

EID: 0033556785     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199902150-00006     Document Type: Article

References (47)

1. Thomas J, Carver M, Cunningham P, Park K, Gonder J. Promotion of incompatible allograft acceptance in rhesus monkeys given posttransplant antithymocyte globulin and donor bone marrow: in vivo parameters and immunohistologic evidence suggesting michrochimerism. Transplantation 1987; 43: 332.
2. Thomas JM, Carver FM, Cunningham PRG, Olson LC, Thomas FT. Kidney allograft tolerance in primates without chronic immunosuppression: the role of veto cells. Transplantation 1991; 51: 198.
3. Thomas JM, Verbanac KM, Thomas FT. The veto mechanism in transplant tolerance. Transplant Rev 1991; 5: 209.
4. Thomas J, Carver M, Foil, B. Transplantation 1983; 36: 104.
5. Fink PJ, Shimonkevitz RP, Bevan MJ. Veto cells. Annu Rev Immunol 1988; 6: 115.
6. Miller RG. The veto phenomenon and transplantation tolerance. In Auchincloss H, ed. Transplantation immunology. Wiley-Liss, Inc., New York, 1995; 267.
7. Heeg K, Wagner H. Induction of peripheral tolerance to class I major histocompatibility complex (MHC alloantigens in adult mice: transfused class I MHC-incompatible splenocytes veto clonal responses of antigen-reactive Lyt-2+ T cells. J Exp Med 1990; 172: 719.
8. Verbanac KM, Carver M, Haisch CE, Thomas JM. A role for transforming growth factor-beta in the veto mechanism in transplant tolerance. Transplantation 1994; 57: 893.
9. Kaplan DR, Hambor JE, Tykocinski, ML. An immuno-regulatory function for the CD8 molecule. Proc Natl Acad Sci USA 1989; 86: 8512.
10. Sambhara SR, Miller RG. Programmed cell death of T cells signaled through the T cell receptor and the α3 domain of class I MHC. Science 1991; 252: 1424.
11. + cells. J Immunol 1990; 145: 1646.
12. Zhang L, Fung-Leung W, Miller RG. Down-regulation of CD8 on mature antigen-reactive T cells as a mechanism of peripheral tolerance. J Immunol 1995; 155: 3464.
13. Woodle SE, Smith DM, Bluestone JA, Kirkman WM III, Green DR, Skowronski EW. Anti-human class I MHC antibodies induce apoptosis by a pathway that is distinct from the Fas antigen-mediated pathway. J Immunol 1997; 158: 2156.
14. Miyazono K, Hellman U, Wernstedt C, Heldin CH. Latent high molecular weight complex of transforming growth factor-β1. J Biol Chem 1988; 263: 6408.
15. Genestier L, Paillot R, Bonnefoy-Berard N, Waldmann H, Revillard JP. T cell sensitivity to HLA class I-mediated apoptosis is dependent on interleuken-2 and interleuken-4. Eur J Immunol 1997; 27: 495.
16. Yang L, Steussy CN, Fuhrer DK, Hamilton J, Yang Y-C. Interleukin-11 mRNA stabilization in phorbol ester-stimulated primate bone marrow stromal cells. Mol Cell Biol 1996; 16: 3300.
17. Ahuja SS, Shrivastav S, Danielpour D, Balow JE, Boumpas DT. Regulation of transforming growth factor-β1 and its receptor by cyclosporine in human T cells. Transplantation 1995; 60: 718.
18. Hiruma K, Gress RE. Cyclosporine A and peripheral tolerance. J Immunol 1992; 149: 1539.
19. Letterio J, Roberts A. Regulation of immune responses by TGF-β1. Annu Rev Immunol 1998; 16: 137.
20. Azuma E, Kaplan J. Role of lymphokine-activated killer cells as mediators of veto and natural suppression. J Immunol 1988; 141: 2601.
21. Miller RG, Zhang L, Sheng-Tanner X-F, Hammad N, Radvanyi L. The veto hypothesis and transplantation tolerance. Transplant Sci 1993; 3: 206.
22. Mathew JM, Carreno M, Fuller L, et al. Modulatory effects of human donor bone marrow cells on allogeneic cellular immune responses. Transplantation 1997; 63: 686.
23. Oberhammer FA, Pavelka M, Sharma S, et al. Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor β1. Proc Natl Acad Sci USA 1992; 89: 5408.
24. Bursch W, Oberhammer F, Jirtle RL, et al. Transforming growth factor β1 as a signal for induction of cell death by apoptosis. Br J Cancer 1993; 67: 531.
25. Takiya S, Tagaya T, Takahashi K, et al. Role of transforming growth factor β1 on hepatic regeneration and apoptosis in liver diseases. J Clin Pathol. 1995; 48: 1093.
26. Weller M, Constam DB, Malipiero U, Fontana A. Transforming growth factor-β2 induces apoptosis of murine T cell clones without down-regulating bcl-2 mRNA expression. Eur J Immunol 1994; 24: 1293.
27. 2+ elevation and cyclosporin A synergistically induce TGF-β1-mediated apoptosis in lymphocytes. J Immunol 1997; 158: 2527.
28. Lomo J, Blomhoff HK, Beiske K, Stokke T, Smeland EB. TGF-β1 and cyclic AMP promote apoptosis in resting human B lymphocytes. J Immunol 1995; 154: 1634.
29. AyanlarBatuman O, Ferrero AP, Diaz A, Jimenez S. Regulation of transforming growth factor-β1 gene expression by glucocorticoids in normal human T lymphocytes. J Clin Invest 1991; 88: 1574.
30. Weller M, Malipiero U, Groscurth P, Fontana A. T cell apoptosis induced by IL-2 deprivation or transforming growth factor-β2: modulation by the phosphatase inhibitors okadaic acid and calyculin A. Exp Cell Res 1995; 221: 395.
31. Kingsley DM. The TGF-β superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev 1994; 8: 133.
32. Cerwenka A, Kovar H, Majdic O, Holter W. Fas- and activation-induced apoptosis are reduced in human T cells preactivated in the presence of TGF-β1. J Immunol 1996; 156: 459.
33. Fink PJ, Rammensee HG, Benedetto JD, Staerz UD, Lefrancois L, Bevan MJ. Studies on the mechanism of suppression of primary cytotoxic responses by cloned cytotoxic T lymphocytes. J Immunol 1984; 133: 1769.
34. Thomas JM, Carver FM, Kasten-Jolly J, et al. Further studies of veto activity in rhesus monkey bone marrow in relation to allograft tolerance and chimerism. Transplantation 1994; 57: 101.
35. Frey RS, Mulder KM. Involvement of extracellular signal-regulated kinase 2 and stress-activated protein kinase/Jun N-terminal kinase activation by transforming growth factor β in the negative growth control of breast cancer cells. Cancer Res 1997; 57: 628.
36. Ichijo H, Nishida E, Irie K, et al. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 1997; 275: 90.
37. Bright JM, Kerr LD, Sriram S. TGF-β inhibits IL-2-induced tyrosine phosphorylation and activation of Jak-1 and Stat 5 in T lymphocytes. J Immunol 1997; 159: 175.
38. Arsura M, Wu M, Sonenshein GE. TGFβ1 inhibits NF-κB/Rel activity inducing apoptosis of B cells: transcriptional activation of IκBα. Immunity 1996; 5: 31.
39. Inge TH, McCoy KM, Susskind BM, Barrett SK, Zhao G, Bear HD. Immunomodulatory effects of transforming factor-β on T lymphocytes. J Immunol 1992; 148: 3847.
40. Kulkarni AB, Ward JM, Yaswen L, et al. Transforming growth factor-β1 null mice: an animal model for inflammatory disorders. Am J Pathol 1995; 146: 264.
41. Yasmen L, Kulkarni AB, Fredrickson T, et al. Autoimmune manifestations in the transforming growth factor-β1 knock-out mouse. Blood 1996; 87: 1439.
42. Ruscetti F, Varesio L, Ochoa A, Ortaldo J. Pleiotropic effects of transforming growth factor-β on cells of the immune system. Ann NY Acad Sci 1993; 685: 488.
43. Wesselborg S, Janseen SO, Kabelitz D. Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells. J Immunol 1993; 150: 4338.
44. Wesselborg SU, Pruffer M, Wild B, Schrave S, Meuer C, Kabelitz D. Triggering via the alternative CD2 pathway induces apoptosis in activated human T lymphocytes. Eur J Immunol 1993; 23: 2707.
45. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449.
46. Kramer PH, Dhein J, Knipping E, et al. The role of APO-1mediated apoptosis in the immune system. Immunol Rev 1994; 142: 175.
47. Li B, Sehajpal PK, Khanna A, Vlassara H et al. Differential regulation of transforming growth factor beta and interleukin 2 genes in human T cells: demonstration by usage of novel competitor DNA constructs in the quantitative polymerase chain reaction. J Exp Med 1991; 174: 1259.